Aveanna Healthcare Reprices $1.3B Debt, Cuts Interest Margin by 0.50%
AVAH sits 97% above its 52-week low of $3.73.
Summary
Aveanna Healthcare successfully repriced its credit facilities, reducing interest rate margins by 0.50% on over $1.3 billion in debt, which will lead to substantial annual interest expense savings.
Key Events · Financing and Capital Events · AVAH
-
Debt Repricing Completed
Aveanna Healthcare LLC, a wholly owned subsidiary, entered into the thirteenth amendment to its First Lien Credit Agreement, repricing its debt facilities.
-
Significant Interest Rate Reduction
The repricing results in a 0.50% reduction to applicable interest rate margins on $1,318,375,000 in senior secured term loans and a $250,000,000 senior secured revolving credit facility.
-
Potential for Further Savings
An additional 0.25% reduction in applicable margins is possible if the company obtains a credit rating of at least B2 or B from certain agencies.
Analysis · AVAH · Industrial Applications And Services
Aveanna Healthcare Holdings has successfully repriced its first lien credit facility and revolving credit facility, reducing the applicable interest rate margins by 0.50%. This amendment refinances over $1.3 billion in term loans and a $250 million revolving credit facility, leading to significant annual interest expense savings and strengthening the company's financial position. This follows a trend of reduced interest expenses noted in the recent Q1 2026 financial results.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.6% of the 1018 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVAH was trading at $7.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.73 to $10.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.